Business Description
Dare Bioscience Inc
NAICS : 325412
SIC : 2834
ISIN : US23666P2002
Total Employee Number:
24Description
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.48 | |||||
Equity-to-Asset | 0.03 | |||||
Debt-to-Equity | 2.2 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -10.58 | |||||
Beneish M-Score | 37.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -59.8 | |||||
3-Year EBITDA Growth Rate | 37.9 | |||||
3-Year EPS without NRI Growth Rate | 35.3 | |||||
3-Year FCF Growth Rate | 29.1 | |||||
3-Year Book Growth Rate | -50 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 213.29 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.5 | |||||
9-Day RSI | 17.37 | |||||
14-Day RSI | 23.32 | |||||
3-1 Month Momentum % | -2.36 | |||||
6-1 Month Momentum % | 6.15 | |||||
12-1 Month Momentum % | -22.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.03 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.88 | |||||
Days Payable | 1075.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.1 | |||||
Shareholder Yield % | -111.43 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53.5 | |||||
Operating Margin % | -1034.57 | |||||
Net Margin % | -1038.98 | |||||
EBITDA Margin % | -860.5 | |||||
FCF Margin % | -878.57 | |||||
OCF Margin % | -858.77 | |||||
ROA % | -49 | |||||
ROIC % | -49.4 | |||||
3-Year ROIIC % | 298.66 | |||||
ROC (Joel Greenblatt) % | -250.64 | |||||
ROCE % | -368.97 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 4.04 | |||||
PS Ratio | 15.82 | |||||
PB Ratio | 25.3 | |||||
Price-to-Tangible-Book | 25.3 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-EBITDA | -0.21 | |||||
EV-to-Revenue | 1.77 | |||||
EV-to-Forward-Revenue | 4.4 | |||||
EV-to-FCF | -0.2 | |||||
Earnings Yield (Greenblatt) % | -588.24 | |||||
FCF Yield % | -53.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DARE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dare Bioscience Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.157 | ||
| EPS (TTM) ($) | -0.96 | ||
| Beta | 1.3108 | ||
| 3-Year Sharpe Ratio | -0.54 | ||
| 3-Year Sortino Ratio | -0.85 | ||
| Volatility % | 35.77 | ||
| 14-Day RSI | 23.32 | ||
| 14-Day ATR ($) | 0.152447 | ||
| 20-Day SMA ($) | 1.898 | ||
| 12-1 Month Momentum % | -22.18 | ||
| 52-Week Range ($) | 1.16 - 3.78 | ||
| Shares Outstanding (Mil) | 14.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dare Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dare Bioscience Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 112 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:30 | In 22 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 21 days | ||
| Virtual Investor Closing Bell | 2026-07-14 16:00 | 2.09 (+4.50%) | ||
| General meeting for 2026 | 2026-06-11 09:00 | 2.00 (+5.82%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 2.84 (+6.77%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 2.84 (+6.77%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 16:30 | 1.40 (+2.19%) | ||
| Annual report for 2025 | 2026-03-26 | 1.40 (+2.19%) |
Show
Entries
Dare Bioscience Inc Frequently Asked Questions
What is Dare Bioscience Inc(DARE)'s stock price today?
The current price of DARE is $1.26. The 52 week high of DARE is $3.78 and 52 week low is $1.16.
When is next earnings date of Dare Bioscience Inc(DARE)?
The next earnings date of Dare Bioscience Inc(DARE) is 2026-08-14 Est..
Does Dare Bioscience Inc(DARE) pay dividends? If so, how much?
Dare Bioscience Inc(DARE) does not pay dividend.
Guru Commentaries on NAS:DARE
No articles.
Press Release
Articles on Dare Bioscience Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers